⌕
Arrowhead Pharmaceuticals · ARWR · Nasdaq
Tenet 33 · Weak
Compare
$43.10−2.51%Market openTenet 33 · Weak
$43.10−1.11 (−2.51%)
Market open · 15-min delayed · as of 11:57 AM ET· Nasdaq · USD

Arrowhead Pharmaceuticals (ARWR) Stock

Arrowhead Pharmaceuticals (ARWR) has a Tenet Score of 33 of 100 against 340 Healthcare peers, as of Nov 16, 2026.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

23 figures withheld by our checks. Each blank figure names its reason.

Key stats

Market cap
$6.2B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
37.06 – 95.49
low → high · as of close, Nov 16, 2026
Tenet Score
33/100
Weak · 340 Healthcare peers

Industry: Drugs

Arrowhead Pharmaceuticals Inc. scores 33/100. Weak. Value is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
33/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
2
Quality
26
Health
62
Growth
44

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityFHealthCGrowthDMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
124.2×
fiscal year to Sep 30, 2026 · as of close, Nov 16, 2026
P/S
13.9×
price to sales, fiscal 2026 · as of close, Nov 16, 2026
ROE
—
Not meaningful: shareholders' equity is under 5% of total assets.
Operating margin
−156.9%
before interest and tax
Net margin
−160.6%
fiscal year to Sep 30, 2026
Current ratio
4.14
fiscal year to Sep 30, 2026
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for th…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 129 US ETFs · top wrappers by weightSee all ETFs holding ARWR →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Arrowhead Pharmaceuticals in?

Arrowhead Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Arrowhead Pharmaceuticals' Tenet Score?

Arrowhead Pharmaceuticals' Tenet Score is 33 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.